SCHEMBL1841180

SCHEMBL1841180

NC(=O)Cc1cc2c(-c3ccnc(N)c3)ccnc2[nH]1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CHUK O15111 5/20 0.59
▸ IKBKB O14920 1/20 0.59
▸ ROCK1 Q13464 1/20 0.59
▸ NUDT1 P36639 6/20 0.47
▸ CCNK O75909 2/20 0.47
▸ CDK12 Q9NYV4 2/20 0.47
▸ BTK Q06187 1/20 0.46
▸ MKNK1 Q9BUB5 1/20 0.42
▸ MKNK2 Q9HBH9 1/20 0.42
▸ INSR P06213 4/20 0.40
▸ MAPK8 P45983 4/20 0.40
▸ CAMKK2 Q96RR4 4/20 0.40
▸ PRKCI P41743 1/20 0.40
▸ DYRK1A Q13627 1/20 0.40
▸ CDC7 O00311 1/20 0.39
▸ GABRP O00591 1/20 0.38
▸ GABRD O14764 1/20 0.38
▸ GABRA1 P14867 1/20 0.38
▸ GABRB1 P18505 1/20 0.38
▸ GABRG2 P18507 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13505067 0.76 IKBKB (0.85) CHUKIKBKBROCK1CCNKCDK12
SCHEMBL2239319 0.76 CHUK (0.51) CHUKIKBKBROCK1NUDT1CCNK
SCHEMBL14279265 0.76 CHUK (0.51) CHUKIKBKBROCK1NUDT1CCNK
SCHEMBL1838419 0.76 CDC7 (0.47) CHUKBTKINSRMAPK8CAMKK2
SCHEMBL3417659 0.74 IKBKB (1.00) CHUKIKBKBROCK1CCNKCDK12
SCHEMBL3412863 0.73 IKBKB (0.89) CHUKIKBKBROCK1CCNKCDK12
SCHEMBL3413368 0.72 IKBKB (0.80) CHUKIKBKBROCK1
SCHEMBL14279263 0.72 CHUK (0.71) CHUKIKBKBROCK1CCNKCDK12
SCHEMBL3417293 0.71 IKBKB (0.78) CHUKIKBKBROCK1
SCHEMBL3415743 0.70 CHUK (0.61) CHUKIKBKBROCK1NUDT1CCNK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2011526931-A — — 2011-10-20 — — JP claimed
US-20110201599-A1 CDK Modulators EXELIXIS, INC. (US) 2011-08-18 — — US claimed
CN-102143746-A CDK modulators EXELIXIS INC 2011-08-03 — — CN claimed
EP-2320895-A2 CDK MODULATORS Exelixis, Inc. (US) 2011-05-18 — — EP claimed
WO-2010003133-A2 CDK MODULATORS EXELIXIS INC. (US) 2010-01-07 — — WO claimed
US-20110201599-A1 CDK Modulators EXELIXIS, INC. (US) 2011-08-18 — — US disclosed
US-20110201599-A1 CDK Modulators EXELIXIS, INC. (US) 2011-08-18 — — US disclosed
US-20110201599-A1 CDK Modulators EXELIXIS, INC. (US) 2011-08-18 — — US disclosed
CN-102143746-A CDK modulators EXELIXIS INC 2011-08-03 — — CN disclosed
WO-2010003133-A2 CDK MODULATORS EXELIXIS INC. (US) 2010-01-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110201599-A1 CDK Modulators CDK3, CDK1, CDKL1 CHUK 163/4885IKBKB 246/4885ROCK1 759/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback